The FDA has approved Wegovy for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced liver fibrosis.Semaglutide 2.4 mg injection (Wegovy ...

The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...

The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.

The liver rarely asks for attention, but when it does, the signs are serious. Fatty liver disease is no longer just linked to ...

The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

Novo Nordisk cuts prices. In a pair of press releases this morning, Novo announced it's cutting the cash cost for 0.5 mg, 1 ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

A total of 237 estimates from 47 studies covering more than 1.5 million cases of any ethnicity were included in the study.

Using a novel 3D culture system, an international team of researchers have created the first vascularized liver organoid.

It’s been more than a year since Browns great Bernie Kosar announced he was placed on a liver transplant list.